A complex crosstalk between polymorphic microRNA target sites and AD prognosis

RNA Biology

Volumn 8, Issue 4, 2011, Pages 665-673

  Mallick, Bibekanand ^a   Ghosh, Zhumur ^b  

^a WADSWORTH CENTER   (United States)

^b BOSE INSTITUTE   (India)

Author keywords

Alzheimer disease; Genetic variation; microRNA; microRNA targets; miRNA target SNP; Neurodegenerative disorder; SNP

Indexed keywords

MICRORNA; MICRORNA 21;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; COGNITION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE CONTROL; GENETIC VARIABILITY; GENOME; MUTATION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURAL BIOINFORMATICS;

EID: 79960105647     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.8.4.15584     Document Type: Article

References (80)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6. (Pubitemid 34790756)
2. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-44.
3. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120:545-55.
4. Guyant-Marechal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 2007; 68:684-7. (Pubitemid 46667816)
5. Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 2006; 78:936-46. (Pubitemid 43787686)
6. Keller L, Welander H, Chiang HH, Tjernberg LO, Nennesmo I, Wallin AK, et al. The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of Abeta in different brain regions. Eur J Hum Genet 2010; 18:1202-8.
7. Dominguez DI, Hartmann D, De Strooper B. BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. Neurodegener Dis 2004; 1:168-74. (Pubitemid 39551793)
8. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41:1088-93.
9. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41:1094-9.
10. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303:1832-40.
11. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008; 105:6415-20. (Pubitemid 351758360)
12. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, et al. MicroRNAs can regulate human APP levels. Mol Neurodegener 2008; 3:10.
13. Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 2008; 28:1213-23. (Pubitemid 351186356)
14. Ghosh Z, Chakrabarti J, Mallick B. miRNomics-The bioinformatics of microRNA genes. Biochem Biophys Res Commun 2007; 363:6-11. (Pubitemid 47440152)
15. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597-610.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116:281-97.
17. Svoboda P. Why mouse oocytes and early embryos ignore miRNAs? RNA Biology 2010; 7:1-5.
18. Barbato C, Ruberti F, Cogoni C. Searching for MIND: microRNAs in neurodegenerative diseases. J Biomed Biotechnol 2009; 2009:871313.
19. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66:7390-4. (Pubitemid 44289189)
20. Haramati S, Chapnik E, Sztainberg Y, Eilam R, Zwang R, Gershoni N, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010; 107:13111-6.
21. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33.
22. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009; 460:479-86.
23. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439:283-9. (Pubitemid 43128846)
24. Smalheiser NR, Lugli G. microRNA regulation of synaptic plasticity. Neuromolecular Med 2009; 11:133-40.
25. Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008; 7:2643-6.
26. Sonntag KC. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res 2010; 1338:48-57.
27. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 2009; 106:13052-7.
28. Szulwach KE, Jin P, Alisch RS. Noncoding RNAs in mental retardation. Clin Genet 2009; 75:209-19.
29. Boissonneault V, Plante I, Rivest S, Provost P. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 2009; 284:1971-81.
30. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med 2008; 14:723-30.
31. Hebert SS, Horre K, Nicolai L, Bergmans B, Papadopoulou AS, Delacourte A, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 2009; 33:422-8.
32. Post SM, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell 2010; 18:220-30.
33. Folkersen L, van't Hooft F, Chernogubova E, Agardh HE, Hansson GK, Hedin U, et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet 2010; 3:365-73.
34. Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008; 65:499-505. (Pubitemid 351549959)
35. Kirschling CM, Kolsch H, Frahnert C, Rao ML, Maier W, Heun R. Polymorphism in the BACE gene influences the risk for Alzheimer's disease. Neuroreport 2003; 14:1243-6. (Pubitemid 36928596)
36. Skipper L, Liu JJ, Tan EK. Polymorphisms in candidate genes: implications for the current treatment of Parkinson's disease. Expert Opin Pharmacother 2006; 7:849-55.
37. Zuo X, Jia J. Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease. Brain Res 2009; 1249:1-8.
38. Elton T, Sansom S, MM M. Trisomy-21 gene dosage overexpression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biology 2010; 7.
39. Georges M, Coppieters W, Charlier C. Polymorphic miRNA-mediated gene regulation: contribution to phenotypic variation and disease. Curr Opin Genet Dev 2007; 17:166-76. (Pubitemid 46843549)
40. Abelson JF, Kwan KY, O'Roak BJ, Baek DY, Stillman AA, Morgan TM, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005; 310:317-20. (Pubitemid 41457198)
41. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet 2006; 38:1452-6. (Pubitemid 44837570)
42. Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010; 70:2789-98.
43. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10:389-402.
44. Lv K, Guo Y, Zhang Y, Wang K, Jia Y, Sun S. Allele-specific targeting of hsa-miR-657 to human IGF2R creates a potential mechanism underlying the association of ACAA-insertion/deletion polymorphism with type 2 diabetes. Biochem Biophys Res Commun 2008; 374:101-5.
45. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, et al. The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007; 282:24262-9. (Pubitemid 47328062)
46. Bettens K, Brouwers N, Engelborghs S, Van Miegroet H, De Deyn PP, Theuns J, et al. APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease. Hum Mutat 2009; 30:1207-13.
47. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008; 82:283-9.
48. Nunez-Iglesias J, Liu CC, Morgan TE, Finch CE, Zhou XJ. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PLoS One 2010; 5:8898.
49. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008; 14:27-41. (Pubitemid 352039013)
50. Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem 2003; 278:3446-54. (Pubitemid 36801261)
51. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics 2007; 28:311-22. (Pubitemid 46708771)
52. Cai D, Zhong M, Wang R, Netzer WJ, Shields D, Zheng H, et al. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci USA 2006; 103:1936-40. (Pubitemid 43228796)
53. Chen H, Shalom-Feuerstein R, Riley J, Zhang SD, Tucci P, Agostini M, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation and control neurite outgrowth in vitro. Biochem Biophys Res Commun 2010; 394:921-7.
54. Cole S, Vassar R. The Alzheimer's disease β-secretase enzyme, BACE1. Mol Neurodegener 2007; 2.
55. Ghahramani Seno MM, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G, et al. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 2010; 1380:85-97.
56. Hubner R, Schmole AC, Liedmann A, Frech MJ, Rolfs A, Luo J. Differentiation of human neural progenitor cells regulated by Wnt-3a. Biochem Biophys Res Commun 2010; 400:358-62.
57. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5:691-701. (Pubitemid 39150127)
58. Pinson KI, Brennan J, Monkley S, Avery BJ, Skarnes WC. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000; 407:535-8.
59. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407:530-5.
60. De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, Major MB, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA 2007; 104:9434-9. (Pubitemid 47185797)
61. Kawasaki H, Taira K. Hes1 is a target of microRNA-23 during retinoic-acid-induced neuronal differentiation of NT2 cells. Nature 2003; 423:838-42. (Pubitemid 36781268)
62. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368:387-403. (Pubitemid 44108123)
63. Orlacchio A, Kawarai T, Polidoro M, Stefani A, Orlacchio A, George-Hyslop P, et al. Association analysis between Alzheimer's disease and the Nicastrin gene polymorphisms. Neuroscience Letters 2002; 333:115-8.
64. Sorbi S, Nacmias B, Forleo P, Latorraca S, Gobbini I, Bracco L, et al. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 1994; 177:100-2. (Pubitemid 24269439)
65. Evangelisti C, Florian M, Massimi I, Dominici C, Giannini G, Galardi S, et al. MiR-128upregulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 2009; 23:4276-87.
66. Dostie J, Mourelatos Z, Yang M, Sharma A, Dreyfuss G. Numerous microRNPs in neuronal cells containing novel microRNAs. RNA 2003; 9:180-6. (Pubitemid 36206286)
67. Schaefer A, Im H, Venø M, Fowler C, Min A, Intrator A, et al. Argonaute 2 in dopamine 2 receptor-expressing neurons regulates cocaine addiction. J Exp Med 2010; 207:1843-51.
68. Strickland D, Kounnas M, Argraves W. LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 1995; 9:890-8.
69. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19:357-60. (Pubitemid 28357907)
70. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:1977-81.
71. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol 1995; 37:211-7.
72. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106:1159-66.
73. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17-23. (Pubitemid 46026496)
74. Schipper HM. The role of biologic markers in the diagnosis of Alzheimer's disease. Alzheimers Dement 2007; 3:325-32. (Pubitemid 47553567)
75. Chertkow H, Nasreddine Z, Joanette Y, Drolet V, Kirk J, Massoud F, et al. Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis. Alzheimers Dement 2007; 3:266-82. (Pubitemid 47553568)
76. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007; 8:215-39.
77. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18:504-11. (Pubitemid 38372808)
78. Mateo I, Vazquez-Higuera JL, Sanchez-Juan P, Rodriguez-Rodriguez E, Infante J, Garcia-Gorostiaga I, et al. Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk. Acta Neurol Scand 2009; 120:130-3.
79. Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 2010; 38:789-802.
80. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10:1507-17. (Pubitemid 39288185)